Show simple item record

dc.contributor.authorMølstad, Per
dc.contributor.authorNordrehaug, Jan Erik
dc.contributor.authorSteigen, Terje
dc.contributor.authorWilsgaard, Tom
dc.contributor.authorWiseth, Rune
dc.contributor.authorBønaa, Kaare Harald
dc.date.accessioned2022-03-30T08:18:46Z
dc.date.available2022-03-30T08:18:46Z
dc.date.issued2021-05
dc.description.abstractBackground: NORSTENT trial randomized 9,013 patients to percutaneous coronary intervention with drug-eluting stents (DES) or bare-metal stents (BMS) with a 5-year follow-up. Among the patients, 5,512 had measured either fasting glucose level or percent glycated hemoglobin (HbA1c) at the index procedure. That cohort constitutes the present study population analyzing mortality and evaluating treatment heterogeneity of randomized stent in diabetic versus nondiabetic subgroups. Results: The cohort consisted of 4,174 (75.7%) patients without diabetes, 716 (13.0%) with known diabetes, and 622 (11.3%) with no diabetes in history but elevated fasting glucose level >7.0 mmol/L or HbA1c >6.5% and therefore defined as new diabetes. Patients with known diabetes had a significantly increased all-cause (hazard ratio [HR] 1.99, 95% CI 1.51–2.62, p < 0.001), cardiac (subhazard ratio [SHR] 2.47, 95% CI 1.55–3.93, p < 0.001), and noncardiac (SHR 1.74, 95% CI 1.23–2.44, p = 0.002) mortality after adjustment for baseline variables. In the follow-up of 5 years, patients with new diabetes, however, had a marginally increased all-cause (HR 1.40, 95% CI 1.01–1.93, p = 0.043) and significantly increased noncardiac mortality (SHR 1.52, 95% CI 1.06–2.20, p = 0.025), but no increase in cardiac mortality (SHR 1.06, 95% CI 0.53–2.12, p = 0.86) after the same adjustment. The majority of the mortality was cardiac in the first 1–2 years after intervention; thereafter, noncardiac mortality dominated. However, the time period for when noncardiac mortality became the dominating cause varied considerably and significantly between the groups. There was no heterogeneity in mortality in response to randomized stent between diabetics and nondiabetics. Conclusion: Known diabetes has increased cardiac and noncardiac mortality in contrast to new diabetes which is only associated with increased noncardiac mortality during the 5-year follow-up. Diabetic and nondiabetic patients have the same response to the treatment with BMS or DES.en_US
dc.descriptionThis is the accepted manuscript version of an article published by S. Karger AG in Cardiology 2021/146/3, available at <a href=https://doi.org/10.1159/000513514>https://doi.org/10.1159/000513514</a>en_US
dc.identifier.citationMølstad, Nordrehaug, Steigen, Wilsgaard, Wiseth, Bønaa. Analyses of Increased Mortality in New and Known Diabetes in Patients with Coronary Disease Enrolled in the NORSTENT Randomized Study. Cardiology. 2021en_US
dc.identifier.cristinIDFRIDAID 1917159
dc.identifier.doi10.1159/000513514
dc.identifier.issn0008-6312
dc.identifier.issn1421-9751
dc.identifier.urihttps://hdl.handle.net/10037/24642
dc.language.isoengen_US
dc.publisherKarger Publishersen_US
dc.relation.journalCardiology
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2021 The Author(s)en_US
dc.titleAnalyses of Increased Mortality in New and Known Diabetes in Patients with Coronary Disease Enrolled in the NORSTENT Randomized Studyen_US
dc.type.versionacceptedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record